Zila Strengthens Management Team

PHOENIX, Feb 23, 2005 (BUSINESS WIRE) -- Zila, Inc. (Nasdaq:ZILA) today announced the most recent addition to its management team with the appointment of Gary V. Klinefelter as Vice President and General Counsel.

Klinefelter, 56, comes to Zila from AMERCO, the parent company of U-Haul International, Inc., where he was corporate secretary and general counsel for the past 16 years. He has extensive experience in business and corporate law, including product acquisitions, real estate, product liability and commercial litigation, international business, federal and state securities law, and corporate governance.

"Gary is a dedicated, highly respected attorney well-versed in all aspects of corporate legal practice," Zila's Chairman, President, and CEO, Doug Burkett, Ph.D., said. "He will take the lead in managing all of our legal affairs, overseeing our corporate legal staff and outside counsel. As Zila's multifaceted business development, regulatory, marketing and financial initiatives generate expansion and growth, it's vital that we have someone with Gary's knowledge and experience on our team."

Other recent additions to the Zila management team include Yu Ping Maguire, Ph.D., Head of Clinical and Regulatory Affairs; George Heiler, Vice President Manufacturing Operations; and G. Warren Chane, Jr., Vice President Corporate Business Development. "Each of these individuals comes to Zila with many years of exceptional pharmaceutical and biotechnology experience at well-respected organizations," Dr. Burkett commented further.

About Zila

Zila, Inc., headquartered in Phoenix, is an innovator in preventative healthcare technologies and products, focusing on enhanced body defense and the detection of pre-disease states. Zila has three business units:

-- Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection through its patented Zila(R) Tolonium Chloride and OraTest(R) technologies. -- Zila Pharmaceuticals, marketer of products to promote oral health and prevent oral disease, including ViziLite(R) oral examination kits, Peridex(R) prescription periodontal rinse and Zilactin(R) OTC oral care products. -- Zila Nutraceuticals, manufacturer and marketer of Ester-C(R) and Ester-E(R), branded, highly effective forms of Advanced Protection vitamins C and E. For more information about Zila, visit www.zila.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, margins, profitability, cash flows and capital needs, the ability of the Company to maintain required cash flows and cash availability to implement its business plan and appreciation in the market value of Zila's common stock. Such factors include, but are not limited to: increased competition from current competitors and new market entrants; the Company's ability to maintain, expand, or in certain cases, regain distribution within new or existing channels of trade for its products; and the market acceptance of the ViziLite(R) and Ester-E(R) products and the future gross margins for such products. A wide variety of factors will impact the length, size and expense of the OraTest(R) clinical program; the FDA's ultimate decision regarding the OraTest(R) clinical program and product; the limitations on the indicated uses for the OraTest(R) product; and the ultimate market reception of the OraTest(R) product. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Report on Form 10-K for its fiscal year ended July 31, 2004, and its Form 10-Q for the three months ended October 31, 2004, filed with the Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.